Brought to you by 
LifeMax gains global license to Novartis' BPR277 for Netherton syndrome
06 Sep 2018
Executive Summary
LifeMax Healthcare International Corp.'s US subsidiary LifeMax Laboratories Inc. secured an exclusive worldwide license to develop, manufacture, and commercialize Novartis Pharma AG's BPR277, a topical ointment in development for Netherton syndrome, a rare genetic disorder affecting the skin, hair, and immune system.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LifeMax gains global license to Novartis' BPR277 for Netherton syndrome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice